Enterprise Value
70.72M
Cash
114.3M
Avg Qtr Burn
-21.96M
Short % of Float
13.01%
Insider Ownership
14.37%
Institutional Own.
65.33%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Korsuva IV (CR845 IV) Details Pruritus with chronic kidney disease , Kidney disease | Approved Quarterly sales | |
Oral Korsuva (CR845) Details Pruritus CKD (Chronic Kidney Disease) Stages 3 - 5 | Phase 3 Data readout | |
Oral Korsuva (CR845) Details Skin disease/disorder, Inflammatory disease, Atopic dermatitis, Atopic pruritus | Phase 3 Interim Update | |
Oral Korsuva (CR845) Details Chronic pruritus, Pruritus associated with notalgia paresthetica | Phase 2 Update | |
Oral Korsuva (CR845) Details Chronic liver disease, Liver disease, Chronic pruritus, Hemophilia, Blood disorder | Failed Discontinued |